MedPath

Motor Cortex Plasticity Response to Theta-Burst Stimulation After Ketone Monoester Supplementation

Not Applicable
Recruiting
Conditions
Healthy Young Adult
Neurophysiology
Registration Number
NCT06799260
Lead Sponsor
Universiti Putra Malaysia
Brief Summary

Transcranial magnetic stimulation is a medical device that can alter motor cortical (M1) excitability through the scalp via various protocols. Among these, intermittent- and continuous-theta burst stimulation (iTBS/cTBS) are increasingly used protocols to enhance or suppress M1 excitability, respectively, beyond stimulation. However, the poor reproducibility and high inter-individual variability in responses to TBS protocols are matters of concern. This study will explore whether ketone monoester supplementation can boost TBS efficacy via their mechanistic convergence on Brain-Derived Neurotrophic Factor (BDNF).

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Healthy young adults (18-35 years old)
  • Right-handed
  • Fully vaccinated against COVID-19
Exclusion Criteria
  • Subjects with contraindications to TMS based on the screening 13-item questionnaire for TMS safety
  • Highly active subjects (athletes)
  • Obese (BMI ≥ 30 kg/m2)
  • Smokers
  • Following intermittent fasting or ketogenic diet
  • Long COVID-19

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Motor evoked potential (MEP)Pre-TBS (baseline) and post-TBS at 0, 5, 10, 20, and 30 minutes.

Peak-to-peak MEP amplitude elicited by single-pulse TMS over the left M1 representation of the first dorsal interosseous (FDI) muscle.

In each MEP measurement, 12 MEP readings will be collected, elicited by single-pulse TMS at an intensity of 120% resting motor threshold and separated by 15 seconds.

In each timepoint post-TBS, the mean value of MEPs (aka, conditioned MEPs) will be averaged and compared to pre-TBS (aka, baseline MEPs) using the following equation: (conditioned MEP amplitude/baseline MEP amplitude) × 100. A value of 90-110 represents no change, while values \< 90% represent suppression and \> 110% facilitation of the M1 plasticity following TBS.

Secondary Outcome Measures
NameTimeMethod
TMSens_Q questionnaireAt 30 minutes post-TBS stimulation

Self-reported side effects using the TMSens_Q questionnaire to evaluate the tolerability of the KME-TBS combination.

Corticospinal excitability indicesPre-KME supplementation and at 1 hour post-KME supplementation

Resting motor threshold (RMT) followed by motor-evoked potential at 120% RMT intensity

Blood pressurePre-supplementation, at 1 hour post-supplementation/pre-TBS stimulation, and serially thereafter every 3-5 minutes until 30 minutes post-TBS

Systolic blood pressure (SBP), Diastolic Blood Pressure (DBP), and Mean Arterial Pressure (MAP) using fully automated oscillometric sphygmomanometer

Heart ratePre-supplementation, at 1 hour post-supplementation/pre-TBS stimulation, and continuously thereafter for 30 minutes post-TBS

Heart rate (bpm) using pulse oximeter

Blood glucosePre-KME supplementation and at 30 minutes post-TBS stimulation

On-site using a portable glucometer

BDNF genetic polymorphismAt the baseline (pre-KME supplementation)

BDNF rs6265 single nucleotide polymorphism

Blood beta-hydroxybutyratePre-KME supplementation and at 30 minutes post-TBS stimulation

On-site using a portable glucometer

Serum brain-derived neurotrophic factorPre-KME supplementation and at 30 minutes post-TBS stimulation

Serum levels of mature brain-derived neurotrophic factor (mBDNF) and pro-BDNF isoforms

Trial Locations

Locations (1)

Hospital Sultan Abdul Aziz Shah

🇲🇾

Serdang, Selangor, Malaysia

© Copyright 2025. All Rights Reserved by MedPath